ClinicalTrials.gg
CompletedNCT04059913Updated May 6, 2022

Evaluate the Efficacy and Safety of Multiple Roxadustat Dosing Regimens for the Treatment of Anemia in Dialysis Participants With Chronic Kidney Disease

A Phase 4 interventional study of Roxadustat in CKD Anemia in Dialysis Participants, sponsored by FibroGen. Completed at 25 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-05-06.

Sponsored by FibroGen · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
318
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies testing roxadustat in Anemia — 2 open to participants now, 4 under way, 3 of them phase 3. roxadustat · Anemia.

Enrollment
10th of 43
318 · median 154
Started
2019
with 1 other
Phase 4
7 of 43
1 open now
Registered
27th of 43
by date
Lead sponsor
20 of 43
FibroGen

Among the 43 studies testing roxadustat in Anemia, this one is the 10th largest by enrollment, is one of 2 that started in 2019, is one of 7 in phase 4, and was the 27th registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

2 of the 43 studies testing roxadustat in Anemia are open now. Recruiting first, the newest first:

All 2 open studies →

About roxadustat

roxadustat: first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing roxadustat in Anemia, or all of them as a file.
02

Study summary

This is a randomized, open-label, multi-center study in dialysis chronic kidney disease (CKD) participants to evaluate the efficacy and relative safety of different dosing regimens of roxadustat over a 36-week treatment period.

There are 3 study periods:

  • Screening Period (up to 4 weeks)
  • Treatment Period (36 weeks)

Part 1: Correction/Conversion Period (Weeks 1-20)

Part 2: Hemoglobin (Hb) Maintenance Period (Weeks 21-36)

  • Follow-up Period (4 weeks)
Read the detailed description

Approximately 102 erythropoiesis stimulating agents (ESA)-naïve participants and 204 ESA-treated participants will be enrolled and randomized respectively in a 1:1 ratio to receive roxadustat at one of 2 starting doses as below:

  • Low weight-based dosing: 70 milligrams (mg) 3 times a week (TIW) for body weight \<60 kilograms (kg) or 100 mg TIW for body weight ≥60 kg
  • Standard weight-based dosing: 100 mg TIW for body weight \<60 kg or 120 mg TIW for body weight ≥60 kg

After 20 weeks of treatment, all eligible participants whose last 2 Hb levels ≥105 grams (g)/liter (L) and change in Hb over the most recent 4 weeks is > - 10 g/L will switch to receive roxadustat for another 16 weeks to evaluate the efficacy and safety of new dosing regimens.

At the end of Week 36, all participants will discontinue roxadustat and enter a 4-week Follow-up Period.

03

Conditions studied

  • CKD Anemia in Dialysis Participants

Keywords

  • Anemia
  • Chronic Kidney Disease Dialysis
  • hemoglobin
  • End stage renal disease
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. CKD with end-stage renal disease (ESRD) on either hemodialysis (HD) or peritoneal dialysis (PD)

Exclusion criteria

Exclusion Criteria:

  1. Positive for any of the following: (HIV), surface antigen (HBsAg), or anti- virus antibody (anti-HCV Ab).
  2. Myocardial infarction, acute coronary syndrome, stroke, seizure, or a thromboembolic event (for example, deep venous thrombosis or pulmonary embolism) within 26 weeks prior to Day 1.
  3. History of , myelodysplastic syndrome, and multiple myeloma.
  4. Chronic inflammatory disease other than glomerulonephritis that could impact erythropoiesis (for example, systemic lupus erythematosis [SLE], rheumatoid arthritis, celiac disease).
  5. gastrointestinal bleeding.
  6. Women of and men with sexual partners of child bearing potential who are not using adequate .
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
318 participants (actual)

Study arms

  • Experimental
    Part 1: ESA-Naïve Participants - Low Weight Based Dosing

    ESA-naïve participants will receive roxadustat 70 mg TIW for body weight 45 to \<60 kg or 100 mg TIW for body weight ≥60 kg.

    Drug: Roxadustat

  • Experimental
    Part 1: ESA-Naïve Participants - Standard Weight Based Dosing

    ESA naïve participants will receive roxadustat 100 mg TIW for body weight 45 to \<60 kg or 120 mg TIW for body weight ≥60 kg.

    Drug: Roxadustat

  • Experimental
    Part 1: ESA-Treated Participants - Low Weight Based Dosing

    ESA-treated participants will receive roxadustat 70 mg TIW for body weight 45 to \<60 kg or 100 mg TIW for body weight ≥60 kg.

    Drug: Roxadustat

  • Experimental
    Part 1: ESA-Treated Participants - Standard Weight Based Dosing

    ESA treated participants will receive roxadustat 100 mg TIW for body weight 45 to \<60 kg or 120 mg TIW for body weight ≥60 kg.

    Drug: Roxadustat

  • Experimental
    Part 2: Roxadustat QW

    Participants will receive roxadustat once a week (QW). Roxadustat dose will be 2-dose step increase from originally planned week 21 TIW per dose amount.

    Drug: Roxadustat

  • Experimental
    Part 2: Roxadustat BIW

    Participants will receive roxadustat twice a week (BIW). Roxadustat dose will be 1-dose step increase from originally planned week 21 TIW per dose amount.

    Drug: Roxadustat

  • Experimental
    Part 2: Roxadustat TIW

    Participants will receive roxadustat TIW. Roxadustat dose will continue per dose adjustment guideline.

    Drug: Roxadustat

Interventions

  • Roxadustat will be dosed orally per dose and schedule specified in the arm description.

    Also known as: FG-4592

06

What researchers measure

Primary outcomes

  1. Part 1 (ESA Naïve): Percentage of Participants who Achieved Hb ≥110 g/L in the First 20 Weeks

    Time frame: Weeks 1 to 20

  2. Part 1 (ESA Treated): Percentage of Participants who Achieved Mean Hb ≥100 g/L Averaged Over Weeks 17 to 21 Visits

    Time frame: Weeks 17 to 21

  3. Part 2: Mean Hb Value Averaged Over Weeks 33 to 37 Visits

    Time frame: Weeks 33 to 37

Secondary outcomes

  1. Part 1: Mean Change in Hb Level From Baseline to Average Over Weeks 17 to 21 Visits

    Time frame: Baseline, Weeks 17 to 21

  2. Part 1 (ESA-Naïve): Percentage of Participants With Mean Hb (Averaged Weeks 17 to 21 Visits) ≥100 g/L

    Time frame: Weeks 17 to 21

  3. Part 2: Percentage of Participants With Mean Hb (Averaged Weeks 33 to 37 Visits) ≥100 g/L

    Time frame: Weeks 33 to 37

07

Study locations

25 sites
  • Investigational Site
    Hefei, Anhui 230601, China
  • Investigational Site
    Lanzhou, Gansu 730030, China
  • Investigational Site
    Guangzhou, Guangdong 510515, China
  • Investigational Site
    Shenzhen, Guangdong 518020, China
  • Investigational Site
    Nanning, Guangxi Province 530021, China
  • Investigational Site
    Zhengzhou, Henan 450052, China
  • Investigational Site
    Wuhan, Hubei 430060, China
  • Investigational Site
    Changsha, Hunan 410008, China
  • Investigational Site
    Baotou, Inner Mongolia Autonomous Region 014010, China
  • Investigational Site
    Nanjing, Jiangsu 210009, China
  • Investigational Site
    Nanchang, Jiangxi 330006, China
  • Investigational Site
    Chang chun, Jilin 130021, China
  • Investigational Site
    Shenyang, Liaoning 110004, China
  • Investigational Site
    Shenyang, Liaoning 110122, China
  • Investigational Site
    Taiyuan, Shanxi 030001, China
  • Investigational Site
    Xi'an, Shanxi 710004, China
  • Investigational Site
    Xi'an, Shanxi 710061, China
  • Investigational Site
    Chengdu, Sichuan 610041, China
  • Investigational Site
    Chengdu, Sichuan 610072, China
  • Investigational Site
    Hangzhou, Zhejiang 310003, China
  • Investigational Site
    Beijing, 100044, China
  • Investigational Site
    Beijing, 100191, China
  • Investigational Site
    Beijing, 100730, China
  • Investigational Site
    Shanghai, 200025, China
  • Investigational Site
    Tianjin, 300052, China
08

References and documents

Publications

  • Natale P, Palmer SC, Jaure A, Hodson EM, Ruospo M, Cooper TE, Hahn D, Saglimbene VM, Craig JC, Strippoli GF. Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease. Cochrane Database Syst Rev. 2022 Aug 25;8(8):CD013751. doi: 10.1002/14651858.CD013751.pub2. PubMed 36005278 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2019 to primary completion in Nov 2021, 29 months.

Of 73 phase 4 interventional studies under Anemia, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 48. This study's 29 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2019
First posted
Aug 16, 2019
StartActual
Jun 11, 2019
Primary completionActual
Nov 19, 2021
CompletionActual
Dec 17, 2021
Last update
May 6, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04059913
Lead sponsor
FibroGen
Responsible party
Sponsor
First posted
Aug 16, 2019
Start date
Jun 11, 2019
Primary completion
Nov 19, 2021
Completion
Dec 17, 2021
Last update
May 6, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Roxadustat

Start the discussion